Product Promotion Network


Genes of human “mutants” point to a new superpower

The search for mutations that conjure medical superpowers has turned up people who are resistant to liver disease, even if they drink like crazy. Big-time biotech company Regeneron Pharmaceuticals says it found people with a gene mutation that seems to leave them mostly immune to “fatty liver” disease, which is widespread in the US as a result of both alcoholism and overeating. Now, the company says, it will partner with gene-silencing specialist Alnylam Pharmaceuticals to create medicines that mimic the effect.

Regeneron runs one of the world’s largest gene-sequencing operations in partnership with the Geisinger Health System, operator of a large hospital network. It has the DNA code and the medical records of thousands of volunteers.

Recommended for You

That allows the company to search for people unusually resistant to certain diseases and then determine if there’s an explanation in their DNA (see “The search for exceptional genomes“). Sign up for The Download

Your daily dose of what’s up in emerging technology

Sign Up Thank you — please check your email to complete your sign up. Incorrect email format

Manage your newsletter preferences

The search for genetic superpowers can lead quickly to new drugs, such as a powerful cholesterol-lowering medicine already being sold by Regeneron.

This time, Regeneron scoured the DNA, blood levels, and electronic records of 46,544 volunteers to look for links to liver damage. They zeroed in on a gene called HSD17B13. They found that folks who lack a working copy of this gene had a 73 percent lower chance of cirrhosis due to drinking, and half as big a chance of other types of cirrhosis.

How the protective effect works isn’t entirely clear. But the two biotech companies say they will now try to create a drug to treat fatty-liver disease. About a quarter of Americans suffer from the condition, according to a report published by the Regeneron scientists in the New England Journal of Medicine on March 21.

Fatty liver is chronic and not always dangerous. The biotech companies say they are looking to treat a specific type called nonalcoholic steatohepatitis, or NASH, which is more likely to lead to liver failure. The liver problem is linked to being overweight, so losing weight can slow it down.

For those who can’t shed the pounds, Regeneron may eventually have a superpower in a vial.

Senate passes controversial anti-sex trafficking bill

The Senate has voted 97-2 to advance the Stop Enabling Sex Traffickers Act, a controversial initiative meant to crack down on sex trafficking on the internet.

The bill would hold websites liable for hosting sex trafficking content by making a change to a key part of the Communications Decency Act. Some free-internet activists — as well as some tech company representatives — have argued that the bill places an unrealistic burden on small website operators, and will ultimately chill online speech. Sex workers have also opposed the legislation.


Ron Wyden (D-OR), a critic of the bill, offered an amendment that might have clarified the bill’s purposes, but it was voted down.

“Today is a dark day for the Internet,” the Electronic Frontier Foundation tweeted, saying that the legislation “will silence online speech by forcing Internet platforms to censor their users.”

Last month, the House of Representatives passed its version of the legislation.

Following the broad support in Congress, President Trump will likely sign the legislation when it reaches his desk, and Ivanka Trump gave the measure her support yesterday. “Passing this important piece of legislation will bring us one step closer to ending sex trafficking online & restoring safety in our communities,” she tweeted.

1 2 3 120